reports
- Guy Sips
Kinepolis Group Acquiring the operations of US movie theatre chain Ema...
Kinepolis will acquire the operations of the US movie theatre chain Emagine Entertainment. Kinepolis will add 14 cinemas to its portfolio, representing 177 screens and 18,000 seats, located in Michigan, Illinois, Indiana, and Wisconsin. Kinepolis expects to complete the acquisition by the end of the year. The agreement represents a transaction value of $105m (€ 91m) for 100% of Emagine's business. An additional earn-out amount of up to $15m (€ 13m) is linked to the growth of the US Box Office du...
- Guy Sips
- Jacob Mekhael
- Wim Hoste
- Jacob Mekhael
UCB Secures FDA approval for Kygevvi in ultra-rare disease TK2d
UCB announced that Kygevvi (doxecitine and doxribtimine) has been granted approval by the US FDA in adults and paediatric patients living with thymidine kinase 2 deficiency (TK2d), with an age of symptom onset on or before 12 years. The approval comes in line with the company's guidance of a decision before YE25, making it the first and only approved treatment in this setting. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 p...
- ING Helpdesk
Benelux Morning Notes
Azelis: Appointment of Boris Cambon-Lalanne as group CFO. Belgian Telecoms: Price increase on most of the non-commercialised products and Scarlet trio. D'Ieteren: Belgian October car registrations down 7%, VW down 20%. Kendrion: Results preview; launching share buyback programme. Kinepolis: Acquires US movie theatre chain Emagine Entertainment for US$105m. Kinepolis: October box office in US/Canada and France attendance drop again. Ontex: Branded activity now fully divested. Philip...
Kinepolis signs agreement to acquire the operations of US movie theatr...
Kinepolis signs agreement to acquire the operations of US movie theatre chain Emagine Entertainment Kinepolis signs agreement to acquire the operations of US movie theatre chain Emagine Entertainment Regulatory release - Inside information 4 November 2025, 7:00 AM CET Kinepolis (Euronext: KIN) has reached an agreement to acquire the operations of the US movie theatre chain Emagine Entertainment. Kinepolis expects to complete the acquisition by the end of the year. As a result of this agreement, Kinepolis will add 14 cinemas to its portfolio, representing 177 screens and 18,000 seats, ...
Kinepolis signe un accord pour l'acquisition des activités de la chaîn...
Kinepolis signe un accord pour l'acquisition des activités de la chaîne de cinémas américaine Emagine Entertainment Kinepolis signe un accord pour l'acquisition des activités de la chaîne de cinémas américaine Emagine Entertainment Information réglementée et privilégiée 4 novembre 2025, 7:00 AM CET Kinepolis (Euronext : KIN) a conclu un accord pour l'acquisition des activités de la chaîne de cinémas américaine Emagine Entertainment. Kinepolis prévoit de finaliser l'acquisition d'ici la fin de l'année. Suite à cet accord, Kinepolis ajoutera 14 cinémas à son portefeuille, représentant 1...
Kinepolis sluit overeenkomst tot overname van de activiteiten van de A...
Kinepolis sluit overeenkomst tot overname van de activiteiten van de Amerikaanse bioscoopketen Emagine Entertainment Kinepolis sluit overeenkomst tot overname van de activiteiten van de Amerikaanse bioscoopketen Emagine Entertainment Gereglementeerd bericht - Voorwetenschap 4 november 2025, 7:00 AM CET Kinepolis (Euronext: KIN) heeft een overeenkomst bereikt tot overname van de activiteiten van de Amerikaanse bioscoopketen Emagine Entertainment. Kinepolis verwacht de overname af te ronden tegen het einde van het jaar. Met deze overeenkomst zal Kinepolis 14 bioscopen toevoegen aan haar...
- David Vagman
- CFA
D'Ieteren/A leap of faith for 2H25, concerns for 2026/BUY
We cut our 2025-28F EPS by 4-5% and target price by 5% to €223 on weaker TVH, PHE and Belron as well as lower multiples, in particular at TVH. We still expect 13% FCFev CAGR 2025-28F and 14% EPS CAGR, on 7% EBIT CAGR. The stock has underperformed 17% since 1H25 and is flat YTD, trading at >40% discount, 11x P/E 2026F, 7% FCFev yield. We remain believers in the long-term story, self-help potential (Belron price/mix, cash/commercial markets, mobile static recalibration, TVH turnaround) but admit t...
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Jacob Mekhael
UCB TRx noise aside, fundamentals remain strong
UCB's Bimzelx is well-positioned with strong 3-year data in HS and competitive performance across PsO, PsA, and axSpA, supporting our peak sales estimate of €5.9b by 2030. Despite premium forward P/E multiples, UCB's projected EPS CAGR (2025–2029), being >3x that of peers, means UCB continues to be an attractive name to own. Earlier in the pipeline, our deep dive into the atopic dermatitis (AD) landscape shows that phase 2a data for galovokimig is promising, with plans to advance to phase 2b. Ac...
- Guy Sips
Biotalys EPA issues proposed registration decision for Evoca
We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Thomas Couvreur
- Wim Hoste
- ING Helpdesk
Benelux Morning Notes
AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
- Jacob Mekhael
UCB Supportive 3-year data for Bimzelx in PsA and axSpA at ACR 2025
UCB announced new 3-year data for Bimzelx in adults with active psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) at ACR 2025. The results show sustained responses in both patient groups, and appear competitive vs. other biologics e.g. Cosentyx in cross-trial comparison. Overall supportive data that should maintain Bimzelx' commercial momentum. ACCUMULATE maintained.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- ING Helpdesk
Benelux Morning Notes
Alfen: Preview - kitchen sinking again? CM.com: New CFO appointed. Cofinimmo: Good results a touch better than forecasts, guidance reconfirmed, DEME Group: Wins strategic position in Brazil. D'Ieteren: State Farm TPA contract details emerge. Signify: 3Q25 results – guidance cut. Xior Student Housing: 5.4% LFL growth and full occupancy – operational trends solid.
UCB SA: 1 director
A director at UCB SA bought 70 shares at 250.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
- ING Helpdesk
Benelux Morning Notes
Aalberts: 3Q in line, FY margin now low end of guidance. Acomo: Going from strength to strength. Ahold Delhaize: New $860m distribution centre for Food Lion. Azelis: Weak 3Q25 as broadly expected, CFO to step down. Barco: Press release ahead of CMD. BE Semiconductor Industries: 3Q25 Results – Delivered on order intake. Econocom: 3Q25 organic growth down to c.3.4%, full year growth guidance confirmed. Heineken: EverGreen 2030. Kinepolis: Weak 3Q25 as expected, with Netherlands at ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.